Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.

Autor: Lazurko C; University of Toronto, Faculty of Medicine, Toronto, ON, Canada., Clark M; Division of Gynecologic Oncology, Yale School of Medicine, New Haven, CT, USA., Pulman K; Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON, Canada., Lennox G; Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON, Canada., May T; Division of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada., Fazelzad R; University Health Network Library and Information Services, Princess Margaret Cancer Centre, Toronto, ON, Canada., Gien LT; Division of Gynecologic Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Zigras T; Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON, Canada. Electronic address: Tiffany.Zigras@thp.ca.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2021 Oct; Vol. 163 (1), pp. 209-214. Date of Electronic Publication: 2021 Jul 27.
DOI: 10.1016/j.ygyno.2021.07.027
Abstrakt: Objective: Low-grade serous ovarian cancer (LGSOC) is a rare form of ovarian cancer that accounts for 5-10% of epithelial ovarian cancers. LGSOCs are difficult to treat as they respond poorly to traditional chemotherapy treatments. This systematic review aims to appraise the literature describing the efficacy of hormone maintenance therapy (HMT) in patients with LGSOC given after cytoreductive surgery.
Methods: Medline, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were searched from inception to November 2020. No language restrictions were applied. Publications describing HMT in the primary setting following cytoreductive surgery with or without chemotherapy in women with LGSOC were included. Publications describing HMT in recurrence, non-LGSOC carcinomas, and in-vitro or animal studies were excluded along with case reports, case series, and conference proceedings. We summarized oncologic outcomes, HMT used, and hormone receptor status where reported. Studies were assessed for risk of bias and quality of evidence.
Results: The literature search identified 14,799 records. Four cohort studies met eligibility criteria. A total of 558 patients were included, of which 127 were treated with HMT. There was significant heterogeneity between studies demonstrated by differences in HMT regimens used, dosing, and study population, leading to various outcomes following treatment with HMT.
Conclusions: Treatment of LGSOC remains a challenge. One retrospective study demonstrated improved progression-free survival following HMT for LGSOC, while two others failed to show significant improvements. However, there is limited data available in the literature which restricts the generalizability of these results. Therefore, well-designed, prospective, and randomized trials are needed to confirm the benefit of HMT in patients with this rare subgroup of ovarian cancer.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: